Page last updated: 2024-08-16

thalidomide and isomethyleugenol

thalidomide has been researched along with isomethyleugenol in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abroun, S; Ahmadvand, M; Chegeni, R; Fard, AD; Hajifathali, A; Kaviani, S; Mohammadi, MM; Noruzinia, M; Saki, N; Soleimani, M; Zonoubi, Z	1
DeZern, AE	1

Trials

1 trial(s) available for thalidomide and isomethyleugenol

Article	Year
Evaluation of H3 histone methylation and colony formation in erythroid progenitors treated with thalidomide and sodium butyrate. Laboratory hematology : official publication of the International Society for Laboratory Hematology, 2013, Volume: 19, Issue:1 Topics: AC133 Antigen; Anemia, Sickle Cell; Antigens, CD; beta-Thalassemia; Butyrates; Cells, Cultured; Erythroid Precursor Cells; Fetal Blood; Fetal Hemoglobin; Glycoproteins; Histones; Humans; Methylation; Peptides; Real-Time Polymerase Chain Reaction; Teratogens; Thalidomide; Up-Regulation	2013

Article

Year

Evaluation of H3 histone methylation and colony formation in erythroid progenitors treated with thalidomide and sodium butyrate.

Laboratory hematology : official publication of the International Society for Laboratory Hematology, 2013, Volume: 19, Issue:1

Topics: AC133 Antigen; Anemia, Sickle Cell; Antigens, CD; beta-Thalassemia; Butyrates; Cells, Cultured; Erythroid Precursor Cells; Fetal Blood; Fetal Hemoglobin; Glycoproteins; Histones; Humans; Methylation; Peptides; Real-Time Polymerase Chain Reaction; Teratogens; Thalidomide; Up-Regulation

2013

Other Studies

1 other study(ies) available for thalidomide and isomethyleugenol

Article	Year
Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse? Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015 Topics: Algorithms; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Approval; Drug Industry; Humans; Karyotyping; Lenalidomide; Methylation; Mutation; Myelodysplastic Syndromes; Prognosis; Risk Assessment; Thalidomide; United States; United States Food and Drug Administration	2015

Article

Year

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?

Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015

Topics: Algorithms; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Approval; Drug Industry; Humans; Karyotyping; Lenalidomide; Methylation; Mutation; Myelodysplastic Syndromes; Prognosis; Risk Assessment; Thalidomide; United States; United States Food and Drug Administration

2015